NO20004931L - Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling - Google Patents

Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling

Info

Publication number
NO20004931L
NO20004931L NO20004931A NO20004931A NO20004931L NO 20004931 L NO20004931 L NO 20004931L NO 20004931 A NO20004931 A NO 20004931A NO 20004931 A NO20004931 A NO 20004931A NO 20004931 L NO20004931 L NO 20004931L
Authority
NO
Norway
Prior art keywords
dexmedetomidine
intensive care
sedation
care units
patient
Prior art date
Application number
NO20004931A
Other languages
English (en)
Other versions
NO20004931D0 (no
NO329194B1 (no
Inventor
Riku Aantaa
Romeo Bachand
Esa Heinonen
Original Assignee
Orion Corp
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26763325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20004931(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp, Abbott Lab filed Critical Orion Corp
Publication of NO20004931D0 publication Critical patent/NO20004931D0/no
Publication of NO20004931L publication Critical patent/NO20004931L/no
Publication of NO329194B1 publication Critical patent/NO329194B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse omhandler en fremgangsmåte til å sedere en pasient mens denne er på en intensivavdeling (intensive care unit; ICU). Fremgangsmåten omfatter å administrere dexmedetomidin eller et farmasøytisk akseptabelt salt derav til en pasient med behov for dette i en tilstrekkelig tidsperiode. Videre omhandler den foreliggende oppfinnelsen en fremgangsmåte til å sedere en pasient på intensivavdelingen ved å administrere dexmedetomidin eller et farmasøytisk akseptabelt salt derav, hvori dexmedetomidin er i det vesentlig det ene aktive agenset eller det ene aktive agenset.
NO20004931A 1998-04-01 2000-09-29 Anvendelse av dexmedetomidin til sedering av en kritisk syk pasient som gis intensivbehandling, hvori pasienten forblir vekkbar og orientert NO329194B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8028798P 1998-04-01 1998-04-01
US11094498P 1998-12-04 1998-12-04
PCT/FI1999/000266 WO1999049854A2 (en) 1998-04-01 1999-03-31 Use of dexmedetomidine for icu sedation

Publications (3)

Publication Number Publication Date
NO20004931D0 NO20004931D0 (no) 2000-09-29
NO20004931L true NO20004931L (no) 2000-09-29
NO329194B1 NO329194B1 (no) 2010-09-13

Family

ID=26763325

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004931A NO329194B1 (no) 1998-04-01 2000-09-29 Anvendelse av dexmedetomidin til sedering av en kritisk syk pasient som gis intensivbehandling, hvori pasienten forblir vekkbar og orientert

Country Status (27)

Country Link
EP (1) EP1069893B1 (no)
JP (1) JP4606581B2 (no)
KR (1) KR20010034728A (no)
CN (1) CN1168441C (no)
AR (1) AR015744A1 (no)
AT (1) ATE347359T1 (no)
AU (1) AU754484B2 (no)
BG (1) BG64540B1 (no)
BR (1) BR9909872A (no)
CA (1) CA2326339C (no)
CZ (1) CZ301013B6 (no)
DE (1) DE69934305T2 (no)
DK (1) DK1069893T3 (no)
EA (1) EA005524B1 (no)
ES (1) ES2278441T3 (no)
GB (1) GB2352972B (no)
HU (1) HU229162B1 (no)
IL (1) IL138416A (no)
NO (1) NO329194B1 (no)
NZ (1) NZ507203A (no)
PL (1) PL192517B1 (no)
PT (1) PT1069893E (no)
SI (1) SI1069893T1 (no)
SK (1) SK286160B6 (no)
TR (1) TR200002837T2 (no)
TW (1) TW552136B (no)
WO (1) WO1999049854A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223931B1 (en) 1999-10-29 2005-12-14 Orion Corporation Use of a imidazole derivative for the treatment or prevention of hypotension and shock
HUP0600241A2 (en) * 2002-04-08 2006-07-28 Mgi Gp Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20060058700A1 (en) * 2004-08-26 2006-03-16 Marro Dominic P Patient sedation monitor
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
PL2244737T3 (pl) 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
SG175979A1 (en) * 2009-05-15 2011-12-29 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
DE102009050016A1 (de) 2009-05-27 2011-05-05 Modine Manufacturing Co., Racine Wärmeübertragereinheit
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013090278A2 (en) 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP5921928B2 (ja) * 2012-03-28 2016-05-24 テルモ株式会社 既希釈デクスメデトミジン製剤
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
WO2015011177A1 (en) 2013-07-24 2015-01-29 I-Tech Ab Use of the enantiomer levomedetomidine as inhibitor for marine biofouling of surfaces
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924233C (en) * 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CN113975273B (zh) * 2020-07-27 2023-07-11 宜昌人福药业有限责任公司 一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) * 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5344840A (en) * 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine

Also Published As

Publication number Publication date
SK14362000A3 (sk) 2002-03-05
GB0024932D0 (en) 2000-11-29
EP1069893B1 (en) 2006-12-06
AU754484B2 (en) 2002-11-14
CZ301013B6 (cs) 2009-10-14
HU229162B1 (hu) 2013-09-30
BR9909872A (pt) 2007-11-20
CA2326339C (en) 2008-12-23
PL343553A1 (en) 2001-08-27
DK1069893T3 (da) 2007-03-19
SI1069893T1 (sl) 2007-04-30
NO20004931D0 (no) 2000-09-29
DE69934305T2 (de) 2007-07-12
PT1069893E (pt) 2007-01-31
EA005524B1 (ru) 2005-04-28
CA2326339A1 (en) 1999-10-07
BG64540B1 (bg) 2005-07-29
BG104797A (en) 2001-07-31
JP4606581B2 (ja) 2011-01-05
GB2352972B (en) 2003-05-21
SK286160B6 (sk) 2008-04-07
EA200001010A1 (ru) 2001-02-26
ES2278441T3 (es) 2007-08-01
KR20010034728A (ko) 2001-04-25
WO1999049854A2 (en) 1999-10-07
HUP0101498A3 (en) 2002-06-28
CZ20003484A3 (cs) 2002-01-16
CN1168441C (zh) 2004-09-29
CN1295473A (zh) 2001-05-16
HUP0101498A1 (hu) 2002-03-28
IL138416A (en) 2005-07-25
ATE347359T1 (de) 2006-12-15
TW552136B (en) 2003-09-11
DE69934305D1 (de) 2007-01-18
JP2002509880A (ja) 2002-04-02
GB2352972A (en) 2001-02-14
EP1069893A2 (en) 2001-01-24
WO1999049854A3 (en) 1999-11-18
TR200002837T2 (tr) 2001-01-22
NZ507203A (en) 2003-03-28
NO329194B1 (no) 2010-09-13
AR015744A1 (es) 2001-05-16
AU3149499A (en) 1999-10-18
IL138416A0 (en) 2001-10-31
PL192517B1 (pl) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20004931L (no) Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling
AUPR177300A0 (en) Therapeutic methods
BRPI0408784A (pt) método para usar um composto
BR9911498A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para tratar de um paciente sofrendo de uma condição onde exista um benefìcio em reduzir a concentração de ácido graxo isento de plasma ou reduzir a frequência cardìaca
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
DE69622031D1 (de) INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
NO20003332L (no) Midisinforløper av aspartylproteaseinhibitorer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
DE50012571D1 (de) Biotin enthaltende galenische formulierung
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE101153T1 (de) Thiazolopyrimidinderivate als angiotensin-iirezeptorantagonisten: verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
NO20032261L (no) Medisinske preparater
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
NO984974L (no) Middel som forbedrer pulmonar sirkulasjon
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ORION CORPORATION, FI

MK1K Patent expired